Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03912324
Other study ID # 4-2019-0109
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 6, 2021
Est. completion date April 2025

Study information

Verified date June 2024
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

New parameters or methods, such as ablation index, have been developed for the quantification of high-frequency energy used in pulmonary vein isolation, but there is no known method for atrial fibrillation considering individual differences in atrial tissue. The atrium is only 1/3 of the thickness of the ventricle and is thinner in women and older than men or young people. The aim of this study was to evaluate the efficacy and safety of radiofrequency energy therapy using atrial individual differences. In order to reflect the thickness of the atrium, we will use the unipolar and bipolar maps and the myocardial thickness map using computed tomography (CT) images. To evaluate the efficacy and safety of energy titration therapy by random assignment of high frequency energy therapy group, CT image application high frequency energy therapy group, and existing empirical high frequency therapy group.


Description:

A. Study design 1. Prospective randomization (Unipolar voltage subtraction map guided PV(pulmonary vein) isolation group vs. CT myocardial thickness map guided PV isolation group vs. Empirical PV isolation group ) 2. Target number of subjects: 480 (160 per group) 3. Rhythm FU : 2012 ACC/AHA/ESC guidelines (Holter monitoring at the baseline, 2 month, and thereafter every 6 months; ECG if the patient has any symptom) 4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines 5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate. B. Progress and rhythm/ECG follow-up 1. To be performed in accordance with the 2012 ACC/AHA/HRS guidelines for AF management 2. Follow-up at 1 weeks, 3 months, and thereafter every 6-month after procedure. 3. Rhythm control at 3 months, and thereafter every 6-month follow-up with Holter 4. If the patient complains of symptoms, ECG will be performed at any time, and rhythm follow-up will be carried out with a Holter or event recorder. C. Follow-up All the patients will be followed-up at 1, 3, 6 months, and thereafter every 6 months. If the patient shows any symptom within the clinical study period, patient will visit the outpatient clinic. ECG will be performed at every outpatient visits, and 24-hour Holter or event recording will be performed every 6 months for 2 years, and every year after 2 years (2012 Heart Rhythm Society/EHRA/European Cardiac Arrhythmia Society Expert Consensus Statement guidelines). If atrial fibrillation or atrial tachycardia lasting more than 30 seconds is observed in 12-lead ECG or Holter, it will be evaluated as recurrence. Recurrence within 3 months after the procedure will be classified as early recurrence, and that after 3 months will be classified as clinical recurrence.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and =20 and =80 years of age 2. Left atrium size < 50mm 3. paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug. 4. Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction) Exclusion Criteria: 1. Patients with persistent or permanent atrial fibrillation 2. Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected 3. Patients with severe renal impairment or CT imaging difficulty using contrast media 4. Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery 5. Patients with active internal bleeding 6. Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs 7. Patients with valvular atrial fibrillation (mitral stenosis >grade 2, mechanical valve, mitral valvuloplasty) 8. Patients with a severe comorbid disease 9. Expected survival < 1 year 10. Drug addicts or alcoholics 11. Patients who cannot read the consent form (illiterates, foreigners, etc.) 12. Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Unipolar voltage subtraction map guided PV isolation group
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes) Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure and Ablation time, and perfusion saline dose Rhythm follow-up after the procedure in accordance with the study design.
CT myocardial thickness map guided PV isolation group
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Empirical PV isolation group
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Locations

Country Name City State
Korea, Republic of Severance Cardiovascular Hospital, Yonsei University Health System Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety evaluation: Procedure-related cardiac complication rate including open cardiac surgery, cerebral infarction, pericardial effusion or cardiac tamponade, hematoma in the inguinal puncture site and vascular complications within 30 days post procedure. within 30 days post procedure
Primary Efficacy evaluation: Atrial fibrillation or atrial tachycardia for at least 30 seconds after 3 months within 1 year without antiarrhythmic medication Defined as atrial fibrillation or atrial tachycardia > 30 sec after 3 months within 1 year; based on the 2012 ACC/AHA/HRS guidelines, 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms Within 1 year after 3 months of procedure
Primary Efficacy evaluation: Major cardiovascular event rate death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure immediate after procedure
Primary Efficacy evaluation: Major cardiovascular event rate death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure 12 months after procedure
Secondary Comparison of procedure time immediate after procedure
Secondary Comparison of ablation time immediate after procedure
Secondary Comparison of hospitalization period immediate after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 1 week after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 3 months after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 6 months after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 12 months after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 18 months after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 24 months after procedure
Secondary Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate 36 months after procedure
Secondary Comparison of re-hospitalization rate after the procedure 1 week after procedure
Secondary Comparison of re-hospitalization rate after the procedure 3 months after procedure
Secondary Comparison of re-hospitalization rate after the procedure 6 months after procedure
Secondary Comparison of re-hospitalization rate after the procedure 12 months after procedure
Secondary Comparison of re-hospitalization rate and number of electrical cardioversion after the procedure 18 months after procedure
Secondary Comparison of re-hospitalization rate after the procedure 24 months after procedure
Secondary Comparison of re-hospitalization rate after the procedure 36 months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 1 week months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 3 months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 6 after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 12 months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 18 months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 24 months after procedure
Secondary Comparison of number of electrical cardioversion after the procedure 36 months after procedure
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4